May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics
Verily, pharmas partner to develop clinical programs
The Verily Life Sciences LLC of Alphabet Inc. (NASDAQ:GOOG) partnered with Novartis AG (NYSE:NVS; SIX:NOVN), Otsuka Holdings Co. Ltd. (Tokyo:4578), Pfizer Inc. (NYSE:PFE) and Sanofi (Euronext:SAN; NASDAQ:SNY) to develop patient-centered clinical research programs using Verily's Project Baseline platform. The partners will collect real-world evidence from patient records, sensors and other digital sources to develop clinical studies in cardiovascular disease, oncology, mental health, dermatology and diabetes.
Amryt merging with Aegerion
Rare diseases company Amryt Pharma plc (LSE:AMYT; ISE:AYP) said it will acquire Aegerion Pharmaceuticals Inc. in a deal valuing the combined company at about $310 million. Aegerion, a subsidiary of Novelion Therapeutics Inc. (NASDAQ:NVLN), markets Myalept metreleptin for lipodystrophy and Juxtapid lomitapide for homozygous familial hypercholesterolemia; Amryt already holds territorial rights to the latter drug...